Table 1.
Characteristics Comparison Among Cardiac Medication Usage Groups
|
No cardiac medications (N = 930) |
Beta‐blocker (N = 260) |
Beta‐blocker and other cardiac medications (N = 343) |
Non‐beta‐blocker cardiac medications (N = 438) |
Total (N = 1971) |
P value | |
|---|---|---|---|---|---|---|
| Age at diagnosis | <0.0001a | |||||
| N | 930 | 260 | 343 | 438 | 1971 | |
| Median | 60.0 | 64.0 | 68.0 | 68.0 | 64.0 | |
| Range | (22.0–91.0) | (37.0–92.0) | (32.0–94.0) | (29.0–92.0) | (22.0–94.0) | |
| Gender | 0.3164a | |||||
| Female | 394 (42.4%) | 98 (37.7%) | 129 (37.6%) | 173 (39.5%) | 794 (40.3%) | |
| Male | 536 (57.6%) | 162 (62.3%) | 214 (62.4%) | 265 (60.5%) | 1177 (59.7%) | |
| mSMART | 0.4016a | |||||
| Standard Risk | 271 (62.9%) | 107 (58.8%) | 116 (56.3%) | 117 (60.9%) | 611 (60.4%) | |
| Intermediate Risk | 110 (25.5%) | 45 (24.7%) | 54 (26.2%) | 44 (22.9%) | 253 (25.0%) | |
| High Risk | 50 (11.6%) | 30 (16.5%) | 36 (17.5%) | 31 (16.1%) | 147 (14.5%) | |
| Missing | 499 | 78 | 137 | 246 | 960 | |
| International Staging System | <0.0001a | |||||
| I | 330 (37.9%) | 92 (36.7%) | 90 (27.2%) | 117 (28.2%) | 629 (33.7%) | |
| II | 385 (44.2%) | 96 (38.2%) | 119 (36.0%) | 172 (41.4%) | 772 (41.3%) | |
| III | 156 (17.9%) | 63 (25.1%) | 122 (36.9%) | 126 (30.4%) | 467 (25.0%) | |
| Missing | 59 | 9 | 12 | 23 | 103 | |
| Performance Score | 0.1287a | |||||
| 0 | 360 (41.6%) | 108 (43.5%) | 126 (39.1%) | 167 (41.6%) | 761 (41.4%) | |
| 1 | 332 (38.4%) | 91 (36.7%) | 107 (33.2%) | 140 (34.9%) | 670 (36.5%) | |
| 2+ | 173 (20.0%) | 49 (19.8%) | 89 (27.6%) | 94 (23.4%) | 405 (22.1%) | |
| Missing | 65 | 12 | 21 | 37 | 135 | |
| Diagnosis Year | <0.0001a | |||||
| 1995–1999 | 240 (25.8%) | 37 (14.2%) | 39 (11.4%) | 91 (20.8%) | 407 (20.6%) | |
| 2000–2004 | 291 (31.3%) | 77 (29.6%) | 108 (31.5%) | 144 (32.9%) | 620 (31.5%) | |
| 2005–2010 | 399 (42.9%) | 146 (56.2%) | 196 (57.1%) | 203 (46.3%) | 944 (47.9%) | |
| Pomalidomide | 0.0144a | |||||
| No | 861 (92.6%) | 229 (88.1%) | 311 (90.7%) | 414 (94.5%) | 1815 (92.1%) | |
| Yes | 69 (7.4%) | 31 (11.9%) | 32 (9.3%) | 24 (5.5%) | 156 (7.9%) | |
| Lenalidomide | 0.0250a | |||||
| No | 578 (62.2%) | 147 (56.5%) | 205 (59.8%) | 295 (67.4%) | 1225 (62.2%) | |
| Yes | 352 (37.8%) | 113 (43.5%) | 138 (40.2%) | 143 (32.6%) | 746 (37.8%) | |
| Thalidomide | 0.2777a | |||||
| No | 668 (71.8%) | 189 (72.7%) | 262 (76.4%) | 331 (75.6%) | 1450 (73.6%) | |
| Yes | 262 (28.2%) | 71 (27.3%) | 81 (23.6%) | 107 (24.4%) | 521 (26.4%) | |
| Stem cell transplant | <0.0001a | |||||
| No | 480 (51.6%) | 116 (44.6%) | 204 (59.5%) | 288 (65.8%) | 1088 (55.2%) | |
| Yes | 450 (48.4%) | 144 (55.4%) | 139 (40.5%) | 150 (34.2%) | 883 (44.8%) | |
| Alkylator | 0.2767a | |||||
| No | 457 (50.7%) | 114 (44.4%) | 167 (49.7%) | 216 (51.6%) | 954 (49.9%) | |
| Yes | 444 (49.3%) | 143 (55.6%) | 169 (50.3%) | 203 (48.4%) | 959 (50.1%) | |
| Missing | 29 | 3 | 7 | 19 | 58 | |
| Anthracycline | <0.0001a | |||||
| No | 694 (77.0%) | 215 (83.7%) | 295 (87.8%) | 371 (88.5%) | 1575 (82.3%) | |
| Yes | 207 (23.0%) | 42 (16.3%) | 41 (12.2%) | 48 (11.5%) | 338 (17.7%) | |
| Missing | 29 | 3 | 7 | 19 | 58 | |
| Bortezomib | 0.0010a | |||||
| No | 677 (75.1%) | 167 (65.0%) | 257 (76.5%) | 328 (78.3%) | 1429 (74.7%) | |
| Yes | 224 (24.9%) | 90 (35.0%) | 79 (23.5%) | 91 (21.7%) | 484 (25.3%) | |
| Missing | 29 | 3 | 7 | 19 | 58 | |
| Carfilzomib | 0.4177a | |||||
| No | 882 (97.9%) | 251 (97.7%) | 328 (97.6%) | 415 (99.0%) | 1876 (98.1%) | |
| Yes | 19 (2.1%) | 6 (2.3%) | 8 (2.4%) | 4 (1.0%) | 37 (1.9%) | |
| Missing | 29 | 3 | 7 | 19 | 58 | |
| Ixazomib | 0.0368a | |||||
| No | 887 (98.4%) | 246 (95.7%) | 328 (97.6%) | 413 (98.6%) | 1874 (98.0%) | |
| Yes | 14 (1.6%) | 11 (4.3%) | 8 (2.4%) | 6 (1.4%) | 39 (2.0%) | |
| Missing | 29 | 3 | 7 | 19 | 58 | |
Kruskal Wallis
a
Chi‐Squared.